Keywords
How to Cite
Abstract
Introduction: Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal condition that affects 10% to 20% of the world population, predominantly young or middle-aged women. It is characterized by symptoms such as abdominal pain, distension, diarrhea or constipation, often aggravated by emotional and dietary factors. Although there is no definitive cure, several therapeutic approaches have been proposed. Methodology: This study carried out an integrative review of the literature in databases such as PubMed, LILACS and Scielo, using the descriptors “Irritable bowel syndrome” and “treatment”. Articles between 2019 and 2024, in English and Portuguese, were considered, strictly following inclusion and exclusion criteria. Results and Discussion: Sixteen studies were evaluated, which assessed the following therapeutic options: LOW FODMAP diet, probiotics, fecal microbiota transplant, amitriptyline, geraniol, plecanatide, rifaximin, vibegron, physical activity and neuromodulators. The combination of dietary, pharmacological and behavioral interventions is essential for the management of IBS. Despite the efficacy of diets and probiotics, long-term adherence may be limited. Pharmacological approaches offer a solution in specific cases, and it is necessary to assess the clinical picture on an individual basis. Conclusion: Although there is no cure, the therapeutic approaches reviewed in this study demonstrate great potential in the management of symptoms.
References
ANKERSEN, D. V. et al. Long-Term Effects of a Web-Based Low-FODMAP Diet Versus Probiotic Treatment for Irritable Bowel Syndrome, Including Shotgun Analyses of Microbiota: Randomized, Double-Crossover Clinical Trial. Journal of Medical Internet Research, v. 23, n. 12, p. e30291, 14 dez. 2021.
ASHA, M. Z.; KHALIL, S. F. H. Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Treatment of Irritable Bowel Syndrome: A systematic review and meta-analysis. Sultan Qaboos University Medical Journal [SQUMJ], v. 20, n. 1, p. 13, 9 mar. 2020.
BLACK, C. J.; FORD, A. C. Best management of irritable bowel syndrome. Frontline Gastroenterology, v. 12, n. 4, p. flgastro-2019-101298, 28 maio 2020.
BÖHN, L. et al. Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome as Well as Traditional Dietary Advice: A Randomized Controlled Trial. Gastroenterology, v. 149, n. 6, p. 1399-1407.e2, nov. 2015.
CHOJNACKI, C. et al. The Usefulness of the Low-FODMAP Diet with Limited Tryptophan Intake in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome. Nutrients, v. 15, n. 8, p. 1837, 1 jan. 2023.
COSTA, S. DE A. L. et al. Uso de probióticos no tratamento de pacientes com síndrome do intestino irritável / Use of probiotics in the treatment of patients with irritable bowel syndrome. Brazilian Journal of Health Review, v. 3, n. 4, p. 11047–11060, 28 ago. 2020.
FORD, A. C. et al. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, v. 402, n. 10414, 1 out. 2023.
FRIED, S. et al. World Gastroenterology Organisation Global Guidelines Síndrome do intestino irritável: uma perspectiva mundial Conteúdo 1 Introdução 2 Diagnóstico da SII 3 Avaliação da SII 4 Manejo clínico da SII, 2009. Disponível em: <https://www.worldgastroenterology.org/UserFiles/file/guidelines/irritable-bowel-syndrome-portuguese-2009.pdf>.
HALKJAER et al. Fecal microbiota transplantation for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. World Journal of Gastroenterology, v. 29, n. 20, p. 3185–3202, 28 maio 2023.
HAMAZAKI, M. et al. Fecal microbiota transplantation in the treatment of irritable bowel syndrome: a single-center prospective study in Japan. BMC Gastroenterology, v. 22, n. 1, 14 jul. 2022.
HARPER, A. et al. The Role of Bacteria, Probiotics and Diet in Irritable Bowel Syndrome. Foods, [S.L.], v. 7, n. 2, p. 13, 26 jan. 2018. MDPI AG. http://dx.doi.org/10.3390/foods7020013.
JAIRALA, I.; DROSSMAN, D. A. Central Neuromodulators in Irritable Bowel Syndrome: Why, How, and When. The American Journal of Gastroenterology, v. 119, n. 7, p. 1272–1284, 1 jul. 2024.
JEONG, B. et al. Low concentrations of tricyclic antidepressants stimulate TRPC4 channel activity by acting as an opioid receptor ligand. American journal of physiology. Cell physiology, v. 324, n. 6, p. C1295–C1306, 1 jun. 2023.
LACY, B. E. et al. Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points. Clinical Therapeutics, mar. 2023.
LACY, B. E. et al. Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double‐blind, placebo‐controlled phase 2 trial. Neurogastroenterology and Motility, v. 34, n. 12, 16 ago. 2022.
LOPES, S. S. et al. EVALUATION OF CARBOHYDRATE AND FIBER CONSUMPTION IN PATIENTS WITH IRRITABLE BOWEL SYNDROME IN OUTPATIENT TREATMENT. Arquivos de Gastroenterologia, v. 56, p. 03–09, 20 maio 2019.
MENEES, S. B.; FRANKLIN, H.; CHEY, W. D. Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older. Clinical Therapeutics, v. 42, n. 7, p. 1406-1414.e4, jul. 2020.
MOLESKI, S. M. Síndrome do intestino irritável (SII). Sidney Kimmel Medical College at Thomas Jefferson University, ste. 2022.
NUNAN, D. et al. Physical activity for treatment of irritable bowel syndrome. The Cochrane Database of Systematic Reviews, v. 6, p. CD011497, 29 jun. 2022.
RICCI, C. et al. Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial. Nutrients, v. 14, n. 19, p. 4208, 10 out. 2022.
RODRIGUES, GILSARA A.; CASSIMIRRO, R. F. O uso de probióticos no alívio dos sintomas dos portadores da síndrome do intestino irritável. Revista Brasileira de Ciências da Vida, v. 6, n. 3, 5 abr. 2018.
SADRIN, S. et al. A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. Digestive and Liver Disease, v. 52, n. 5, p. 534–540, maio 2020.
SILVA, M. T. et al. Diagnóstico e tratamento da síndrome do intestino irritável: revisão sistemática. Pará Research Medical Journal, v. 4, 2020.
TSUI, W.; SANTOS, G. C. DOS; ALMEIDA, S. G. DE. Manejo nutricional no tratamento da síndrome do intestino irritável (SII). Research, Society and Development, v. 12, n. 6, p. e13612642135–e13612642135, 14 jun. 2023.
XU, H. et al. Adjunctive treatment with probiotics partially alleviates symptoms and reduces inflammation in patients with irritable bowel syndrome. Eur J Nutr, p. 2553–2565, 2021.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Ana Luisa Albuquerque Miranda, Isabella Ferreira Silva, Marina Messias Murad, Leticia Silva Cavalcante, Tamara Trevenzoli de Souza Lima Tartaglia, Fábio Ruela de Oliveira Ramos, Sarah Maria Mol Fialho, Aliny Barbosa Mucci, Ranielle Bruno dos Santos, Gustavo Batista Mendes Costa Nunes, Ana Luísa Esteves de Barcellos Emery Pereira, Diogo Vieira de Morais, Christiane Alves de Sousa